Sagimet Biosciences Plans Phase 3 Denifanstat Trial for Acne Treatment in 2026

Key Takeaways

• Sagimet plans to initiate Phase 3 clinical trial of denifanstat for moderate to severe acne in the second half of 2026
• The company’s TVB-3567 FASN inhibitor is currently in first-in-human Phase 1 trials
• Further MASH development will only proceed with non-dilutive funding secured

---

Sagimet Biosciences Inc. (Nasdaq: SGMT) announced strategic updates on April 27, 2026, outlining its clinical development timeline for denifanstat, a potential breakthrough treatment for moderate to severe acne.

Phase 3 Acne Trial Timeline

The San Mateo-based clinical-stage biopharmaceutical company plans to launch its pivotal Phase 3 clinical trial of denifanstat in the second half of 2026. This represents a significant milestone for patients suffering from moderate to severe acne, a condition affecting millions of Americans and representing a substantial unmet medical need.

Denifanstat’s mechanism of action and previous clinical data suggest it could offer a novel approach to acne treatment, potentially providing an alternative to existing therapies that may have limitations in efficacy or tolerability.

Pipeline Developments

Concurrently, Sagimet is advancing TVB-3567, a fatty acid synthase (FASN) inhibitor, through its first-in-human Phase 1 clinical trial. FASN inhibitors represent an emerging therapeutic class with potential applications across multiple disease areas.

The company has taken a strategic approach to its metabolic dysfunction-associated steatohepatitis (MASH) program, indicating that further development will depend on securing non-dilutive funding. This measured approach reflects current market conditions and the company’s commitment to prudent capital allocation.

Market Implications

The acne therapeutics market represents a significant commercial opportunity, with current treatments often associated with side effects or limited efficacy in severe cases. Denifanstat’s progression to Phase 3 trials indicates promising earlier-stage results and positions Sagimet to potentially capture market share in this underserved segment.

Upcoming Investor Event

Sagimet will host a key opinion leader (KOL) event and webcast on April 30 at 2 PM ET, providing additional insights into their strategic direction and clinical programs.

---

Frequently Asked Questions

What does this mean for acne patients?

The Phase 3 trial of denifanstat could provide a new treatment option for patients with moderate to severe acne, potentially offering improved efficacy or tolerability compared to existing therapies.

When will denifanstat be available for acne treatment?

The Phase 3 trial is planned to start in the second half of 2026. If successful, regulatory approval and market availability would likely follow 2-3 years after trial completion.

How does denifanstat compare to existing acne treatments?

Specific comparative data hasn’t been disclosed, but denifanstat’s advancement to Phase 3 suggests it demonstrated promising efficacy and safety in earlier trials, potentially offering advantages over current standard-of-care treatments.